MX363077B - Inhibidores de metastasis. - Google Patents

Inhibidores de metastasis.

Info

Publication number
MX363077B
MX363077B MX2015014036A MX2015014036A MX363077B MX 363077 B MX363077 B MX 363077B MX 2015014036 A MX2015014036 A MX 2015014036A MX 2015014036 A MX2015014036 A MX 2015014036A MX 363077 B MX363077 B MX 363077B
Authority
MX
Mexico
Prior art keywords
metastasis
inhibitors
methods
inhibiting
cancers
Prior art date
Application number
MX2015014036A
Other languages
English (en)
Other versions
MX2015014036A (es
Inventor
Parikh Indu
B Adler Kenneth
Original Assignee
Biomarck Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarck Pharmaceuticals Ltd filed Critical Biomarck Pharmaceuticals Ltd
Publication of MX2015014036A publication Critical patent/MX2015014036A/es
Publication of MX363077B publication Critical patent/MX363077B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un compuesto inhibidor de MACKS para usarse en la fabricación de un medicamento para inhibir la metástasis de células cancerosas, en donde el compuesto inhibidor de MARCKS es un péptido que tiene una secuencia de aminoácidos seleccionada del grupo consistente en la SEQ ID NO: 1 a la SEQ ID NO: 231, la SEQ ID NO: 234 y la SEQ ID NO: 235, estando modificado químicamente el aminoácido N-terminal y/o C-terminal de la secuencia peptídica.
MX2015014036A 2013-04-05 2014-04-07 Inhibidores de metastasis. MX363077B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361808966P 2013-04-05 2013-04-05
PCT/US2014/033206 WO2014165853A1 (en) 2013-04-05 2014-04-07 Inhibitors of metastasis

Publications (2)

Publication Number Publication Date
MX2015014036A MX2015014036A (es) 2016-02-25
MX363077B true MX363077B (es) 2019-03-07

Family

ID=51654619

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014036A MX363077B (es) 2013-04-05 2014-04-07 Inhibidores de metastasis.

Country Status (20)

Country Link
US (4) US9408886B2 (es)
EP (1) EP2981279B1 (es)
JP (1) JP6449849B2 (es)
KR (1) KR102191695B1 (es)
CN (1) CN105517562B (es)
AU (1) AU2014247979B2 (es)
BR (1) BR112015025398A2 (es)
CA (1) CA2908832C (es)
DK (1) DK2981279T3 (es)
ES (1) ES2714863T3 (es)
HK (1) HK1221159A1 (es)
HU (1) HUE043971T2 (es)
IL (1) IL241937B (es)
MX (1) MX363077B (es)
PL (1) PL2981279T3 (es)
PT (1) PT2981279T (es)
RU (1) RU2681213C2 (es)
SG (2) SG11201508249WA (es)
WO (1) WO2014165853A1 (es)
ZA (1) ZA201508010B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2714863T3 (es) 2013-04-05 2019-05-30 Biomarck Pharmaceuticals Ltd Péptidos del inhibidor de MARCKS para la inhibición de metástasis
CN108686220A (zh) * 2018-07-13 2018-10-23 刘慧荣 一种针对甲状腺癌的抗肿瘤剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
ATE519493T1 (de) 2001-06-26 2011-08-15 Univ North Carolina State Blockierendes peptid für die sekretion von entzündungszellen
AU2002362753B9 (en) * 2001-10-05 2008-05-15 The Trustees Of The University Of Pennsylvania Compositions for and methods of treating and preventing sirs/sepsis
DE60308251T2 (de) 2002-04-17 2007-08-30 Canon K.K. Vorrichtung zur Bereitstellung von öffentlichen Schlüsselzertifikaten
CN101146545B (zh) 2005-01-20 2012-12-26 拜欧马克医药有限公司 基于mans的结构的粘蛋白分泌过多抑制剂和应用方法
WO2006086681A2 (en) 2005-02-09 2006-08-17 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting smooth muscle cell migration and proliferation
CN103990111B (zh) * 2006-07-26 2016-08-31 拜欧马克医药有限公司 减少炎症介质释放的方法和可用于该方法的肽
CA2664844A1 (en) 2006-10-06 2008-10-23 Celtaxsys, Inc. Chemorepulsion of cells
AU2007318115A1 (en) 2006-10-27 2008-05-15 George Mason Intellectual Properties, Inc. Assay for metastatic colorectal cancer
WO2009062128A2 (en) 2007-11-08 2009-05-14 Indiana University Research And Technology Corporation Combination drug therapy for the treatment of cancer
EP2105511A1 (en) * 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
US9073974B2 (en) * 2009-12-21 2015-07-07 The Regents Of The University Of California RGD-containing cyclic peptides
EP2697386B1 (en) * 2011-04-08 2017-11-01 Tufts Medical Center, Inc. Pepducin design and use
ES2714863T3 (es) * 2013-04-05 2019-05-30 Biomarck Pharmaceuticals Ltd Péptidos del inhibidor de MARCKS para la inhibición de metástasis

Also Published As

Publication number Publication date
CN105517562A (zh) 2016-04-20
RU2015146997A (ru) 2017-05-15
US11466054B2 (en) 2022-10-11
US20140302057A1 (en) 2014-10-09
EP2981279A1 (en) 2016-02-10
EP2981279B1 (en) 2018-12-19
JP6449849B2 (ja) 2019-01-09
US20170121369A1 (en) 2017-05-04
MX2015014036A (es) 2016-02-25
HUE043971T2 (hu) 2019-09-30
IL241937B (en) 2019-03-31
BR112015025398A2 (pt) 2017-10-10
DK2981279T3 (en) 2019-03-25
JP2016516756A (ja) 2016-06-09
KR20150140736A (ko) 2015-12-16
US9408886B2 (en) 2016-08-09
PL2981279T3 (pl) 2019-09-30
AU2014247979A1 (en) 2015-10-29
NZ712955A (en) 2021-03-26
ES2714863T3 (es) 2019-05-30
HK1221159A1 (zh) 2017-05-26
SG10201708125PA (en) 2017-11-29
ZA201508010B (en) 2017-01-25
RU2681213C2 (ru) 2019-03-05
US10011636B2 (en) 2018-07-03
KR102191695B1 (ko) 2020-12-16
RU2015146997A3 (es) 2018-03-13
CA2908832C (en) 2023-01-24
CA2908832A1 (en) 2014-10-09
CN105517562B (zh) 2018-12-28
AU2014247979B2 (en) 2018-06-28
WO2014165853A1 (en) 2014-10-09
US20190119320A1 (en) 2019-04-25
US10683328B2 (en) 2020-06-16
US20210130403A1 (en) 2021-05-06
EP2981279A4 (en) 2016-11-09
PT2981279T (pt) 2019-03-14
SG11201508249WA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
PH12017502141A1 (en) Compounds and their methods of use
HK1252149A1 (zh) 使用pd-l1亞型識別、評估、預防和治療癌症的組合物和方法
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
PH12017501999A1 (en) K-ras modulators
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
PH12015501997A1 (en) Compositions and methods for diagnosis and treatment of hepatic cancers
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
EP3085380A4 (en) Composition for treating prostate cancer
MY180834A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
PH12017501879A1 (en) Methods for treating cancer
PH12015501038A1 (en) Inhibitors of iap
MX2015013021A (es) 5-bromo-indirrubinas.
MX2016016507A (es) Composiciones y metodos para tratar canceres.
MX2021006326A (es) Inhibidores de pcna.
WO2012170742A3 (en) Treatment and prevention of cancer with hmgb1 antagonists
MX2015007608A (es) Metodos y composiciones para inhibir cnksr1.
MX2015014036A (es) Inhibidores de metastasis.